206 research outputs found

    Acoustic wave controlled X-ray diffraction and emission processes in crystals

    Get PDF
    Possibilities to exert control over electromagnetic processes in a crystal by an acoustic wave are considered. The influence of such a wave on the parametric X-ray radiation and coherent bremsstrahlung from relativistic electrons in a crystal are studied in this paper

    Polarization lidars with conical scanning for retrieving the microphysical characteristics of cirrus clouds

    Get PDF
    The paper presents the first results of observations of cirrus clouds by polarization lidars with conical scanning, which were developed in Hefei (China) and in Tomsk (Russia). The light scattering matrix of ice crystal particles of cirrus clouds has been calculated for the first by the authors within the framework of the physical optics approximations in the case of conical scanning lidar. It is found that in this case the Mueller matrix consists of ten non-zero elements, four of which are small and can’t be applied to interpret the azimuthal distribution of particle orientation. All the diagonal elements have a strong azimuthal dependence. Among the off-diagonal elements only one element M34 carries additional information for interpreting the azimuthal distribution. Β© (2015) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only

    ДиагностичСскиС ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠΈ идиопатичСских Π²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹Ρ… ΠΌΠΈΠΎΠΏΠ°Ρ‚ΠΈΠΉ. ΠŸΡ€ΠΎΠ±Π»Π΅ΠΌΡ‹ ΠΈΡ… ΠΎΠΏΡ‚ΠΈΠΌΠΈΠ·Π°Ρ†ΠΈΠΈ

    Get PDF
    The paper deals with the problems of optimizing the diagnostic criteria for idiopathic inflammatory myopathies (IIM), a group of heterogeneousΒ rare autoimmune diseases characterized by inflammatory lesion in the skeletal muscles. The representatives of this group are traditionally consideredΒ to be polymyositis (PM), dermatomyositis (DM), and inclusion-body myositis. The authors detail the history of classification criteria forΒ IIM from those proposed by T.A. Medsger et al. (1970) relying on its clinical picture, laboratory data and instrumental findings, as well as theΒ criteria (including the first introduced exclusion ones) elaborated by A. Bohan and J.B. Peter in 1975, which remain fundamental in both clinicalΒ practice and researches. The basis for the clinical and serological criteria proposed by Y. Troyanov et al. (2005) for IIM is the identificationΒ of myositis-overlap syndromes. The classificational (subtype identification) and therapeutic value of the criteria based on clinical and serologicalΒ characteristics was supported by the Hungarian investigators A. Vancsa et al. (2010) who investigated the relationship between the clinicalΒ and therapeutic characteristics of IIM and positivity for myositis-specific and myositis-associated antibodies. The criteria developed byΒ M.C. Dalakas (1991, 2003) are based on the specific immunopathological features of a histological pattern, which allow the differentiation ofΒ DM, PM, and inclusion-body myositis from other myopathic syndromes. The 2004 European Neuromuscular Center (ENMC) criteria first identifyΒ necrotizing autoimmune myopathy and nonspecific myositis as individual subtypes. The serological classification of IIM, which is based onthe assessment of autoantibodies that play an important role in the pathogenesis of the disease, is of indubitable interest.Β There is an obvious need for the correct and timely diagnosis of both IIM as a whole and its subtypes in particular, which is complicated by theheterogeneity of the latter. The proposed approaches to diagnosing and classifying IIM have their advantages and disadvantages so that workΒ in this direction is yet to be under way.Π‘Ρ‚Π°Ρ‚ΡŒΡ посвящСна ΠΏΡ€ΠΎΠ±Π»Π΅ΠΌΠ°ΠΌ ΠΎΠΏΡ‚ΠΈΠΌΠΈΠ·Π°Ρ†ΠΈΠΈ диагностичСских ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠ΅Π² идиопатичСских Π²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹Ρ… ΠΌΠΈΠΎΠΏΠ°Ρ‚ΠΈΠΉ (Π˜Π’Πœ) – Π³Ρ€ΡƒΠΏΠΏΡ‹ Ρ€Π΅Π΄ΠΊΠΈΡ… Π°ΡƒΡ‚ΠΎΠΈΠΌΠΌΡƒΠ½Π½Ρ‹Ρ… Π³Π΅Ρ‚Π΅Ρ€ΠΎΠ³Π΅Π½Π½Ρ‹Ρ… Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, Ρ…Π°Ρ€Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ·ΡƒΡŽΡ‰ΠΈΡ…ΡΡ Π²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΌ ΠΏΠΎΡ€Π°ΠΆΠ΅Π½ΠΈΠ΅ΠΌ скСлСтной мускулатуры.Β ΠŸΡ€Π΅Π΄ΡΡ‚Π°Π²ΠΈΡ‚Π΅Π»ΡΠΌΠΈ этой Π³Ρ€ΡƒΠΏΠΏΡ‹ Ρ‚Ρ€Π°Π΄ΠΈΡ†ΠΈΠΎΠ½Π½ΠΎ ΡΡ‡ΠΈΡ‚Π°ΡŽΡ‚ΡΡ ΠΏΠΎΠ»ΠΈΠΌΠΈΠΎΠ·ΠΈΡ‚ (ПМ), Π΄Π΅Ρ€ΠΌΠ°Ρ‚ΠΎΠΌΠΈΠΎΠ·ΠΈΡ‚ (Π”M) ΠΈ ΠΌΠΈΠΎΠ·ΠΈΡ‚ с Π²ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΡΠΌΠΈ. ΠŸΠΎΠ΄Ρ€ΠΎΠ±Π½ΠΎ рассмотрСна история создания классификационных ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠ΅Π² Π˜Π’Πœ, начиная с ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠ΅Π² Π’.А. Medsger ΠΈ соавт. (1970), ΠΎΠΏΠΈΡ€Π°ΡŽΡ‰ΠΈΡ…ΡΡ Π½Π° ΠΊΠ»ΠΈΠ½ΠΈΡ‡Π΅ΡΠΊΡƒΡŽ ΠΊΠ°Ρ€Ρ‚ΠΈΠ½Ρƒ, Π»Π°Π±ΠΎΡ€Π°Ρ‚ΠΎΡ€Π½Ρ‹Π΅ Π΄Π°Π½Π½Ρ‹Π΅ ΠΈ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ ΠΈΠ½ΡΡ‚Ρ€ΡƒΠΌΠ΅Π½Ρ‚Π°Π»ΡŒΠ½Ρ‹Ρ… исслСдований, Π° Ρ‚Π°ΠΊΠΆΠ΅ ΠΏΡ€Π΅Π΄Π»ΠΎΠΆΠ΅Π½Π½Ρ‹Ρ… Π² 1975 Π³. А. Bohan ΠΈ J.B. Peter ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠ΅Π² (Π² Ρ‚ΠΎΠΌ числС Π²ΠΏΠ΅Ρ€Π²Ρ‹Π΅ Π²Π²Π΅Π΄Π΅Π½Π½Ρ‹Ρ… ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠ΅Π² ΠΈΡΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΡ), ΠΎΡΡ‚Π°ΡŽΡ‰ΠΈΡ…ΡΡ ΠΎΡΠ½ΠΎΠ²ΠΎΠΏΠΎΠ»Π°Π³Π°ΡŽΡ‰ΠΈΠΌΠΈ ΠΊΠ°ΠΊ Π² клиничСской ΠΏΡ€Π°ΠΊΡ‚ΠΈΠΊΠ΅, Ρ‚Π°ΠΊ ΠΈ Π² Π½Π°ΡƒΡ‡Π½Ρ‹Ρ… исслСдованиях. Π’ основС ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-сСрологичСских ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠ΅Π² Π˜Π’Πœ Y. Troyanov ΠΈ соавт. (2005) Π»Π΅ΠΆΠΈΡ‚ Π²Ρ‹Π΄Π΅Π»Π΅Π½ΠΈΠ΅ пСрСкрСстных overlap-синдромов ΠΌΠΈΠΎΠ·ΠΈΡ‚Π°. ΠšΠ»Π°ΡΡΠΈΡ„ΠΈΠΊΠ°Ρ†ΠΈΠΎΠ½Π½ΠΎΠ΅ (Π²Ρ‹Π΄Π΅Π»Π΅Π½ΠΈΠ΅ субтипов) ΠΈ тСрапСвтичСскоС Π·Π½Π°Ρ‡Π΅Π½ΠΈΠ΅Β ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠ΅Π², основанных Π½Π° ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-сСрологичСской характСристикС, ΠΏΠΎΠ΄Π΄Π΅Ρ€ΠΆΠ°Π½ΠΎ вСнгСрскими исслСдоватСлями A. VΠ°ncsa ΠΈ соавт.Β (2010), ΠΊΠΎΡ‚ΠΎΡ€Ρ‹ΠΌΠΈ ΠΈΠ·ΡƒΡ‡Π΅Π½Π° связь клиничСских ΠΈ тСрапСвтичСских характСристик Π˜Π’Πœ с ΠΏΠΎΠ·ΠΈΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒΡŽ ΠΏΠΎ ΠΌΠΈΠΎΠ·ΠΈΡ‚-спСцифичСским и миозитссоциированным Π°Π½Ρ‚ΠΈΡ‚Π΅Π»Π°ΠΌ. ΠšΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠΈ М.Π‘. Dalakas (1991, 2003) ΠΎΡΠ½ΠΎΠ²Ρ‹Π²Π°ΡŽΡ‚ΡΡ Π½Π° спСцифичСских иммунопатологичСских особСнностях гистологичСской ΠΊΠ°Ρ€Ρ‚ΠΈΠ½Ρ‹, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡŽΡ‰ΠΈΡ… Π΄ΠΈΡ„Ρ„Π΅Ρ€Π΅Π½Ρ†ΠΈΡ€ΠΎΠ²Π°Ρ‚ΡŒ Π”Πœ ΠΈ ПМ, Π° Ρ‚Π°ΠΊΠΆΠ΅ ΠΌΠΈΠΎΠ·ΠΈΡ‚ с Π²ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΡΠΌΠΈ ΠΎΡ‚ других миопатичСских синдромов. Π’ критСриях European Neuromuscular Centre (ENMC) 2004 Π³. Π²ΠΏΠ΅Ρ€Π²Ρ‹Π΅ Π²Ρ‹Π΄Π΅Π»Π΅Π½Ρ‹ ΠΊΠ°ΠΊ ΠΎΡ‚Π΄Π΅Π»ΡŒΠ½Ρ‹Π΅ субтипы аутоиммунная Π½Π΅ΠΊΡ€ΠΎΡ‚ΠΈΠ·ΠΈΡ€ΡƒΡŽΡ‰Π°Ρ миопатия ΠΈ нСспСцифичСский ΠΌΠΈΠΎΠ·ΠΈΡ‚. НСсомнСнный клиничСский интСрСс прСдставляСт сСрологичСская классификация Π˜Π’Πœ, которая базируСтся Π½Π° ΠΎΡ†Π΅Π½ΠΊΠ΅ Π°ΡƒΡ‚ΠΎΠ°Π½Ρ‚ΠΈΡ‚Π΅Π», ΠΈΠ³Ρ€Π°ΡŽΡ‰ΠΈΡ… Π²Π°ΠΆΠ½ΡƒΡŽ Ρ€ΠΎΠ»ΡŒ Π² ΠΏΠ°Ρ‚ΠΎΠ³Π΅Π½Π΅Π·Π΅ заболСвания.Β ΠžΡ‡Π΅Π²ΠΈΠ΄Π½Π° Π½Π΅ΠΎΠ±Ρ…ΠΎΠ΄ΠΈΠΌΠΎΡΡ‚ΡŒ ΠΏΡ€Π°Π²ΠΈΠ»ΡŒΠ½ΠΎΠΉ ΠΈ своСврСмСнной диагностики ΠΊΠ°ΠΊ Π˜Π’Πœ Π² Ρ†Π΅Π»ΠΎΠΌ, Ρ‚Π°ΠΊ ΠΈ Π΅Π³ΠΎ субтипов Π² частности, которая ослоТняСтся Π½Π΅ΠΎΠ΄Π½ΠΎΡ€ΠΎΠ΄Π½ΠΎΡΡ‚ΡŒΡŽ послСдних. ΠŸΡ€Π΅Π΄Π»Π°Π³Π°Π΅ΠΌΡ‹Π΅ ΠΏΠΎΠ΄Ρ…ΠΎΠ΄Ρ‹ ΠΊ диагностикС ΠΈ классификации Π˜Π’Πœ ΠΈΠΌΠ΅ΡŽΡ‚ свои прСимущСства ΠΈ нСдостатки, Ρ‚Π°ΠΊ Ρ‡Ρ‚ΠΎ Ρ€Π°Π±ΠΎΡ‚Π° Π² этом Π½Π°ΠΏΡ€Π°Π²Π»Π΅Π½ΠΈΠΈ Π΅Ρ‰Π΅ прСдстоит

    Efficacy and tolerability of abatacept treatment: results of 12 months observation

    Get PDF
    Objectives: This article reports 1-year clinical outcomes of patients with rheumatoid arthritis (RA) receiving abatacept (ABA) therapy. Materials and methods: Patients (n=91) with high RA activity (DAS28 = 5.1 Β± 1.0) and an inadequate response on synthetic DMARDs (mainly methotrexate, 70.3%) and biologics (mainly TNF-Ξ± inhibitors, 93%) were included in the study. The majority of patients were middle-aged (49 Β± 13.5) womens, RF (72.5%) and ACPA (77%) positive, with moderate functional impairment - HAQ = 1.4 (0.9-2). ABA were administered IV, 10 mg/kg according to the standard scheme. The evaluation of the effectiveness of the therapy was carried out according to the EULAR / ACR 2011 criteria using SDAI, CDAI, HAQ and the intention to treat approach. Results: ABA led to a significant (
    • …
    corecore